Current Headlines

  1. Karolinska Institutet Links With Moderna In mRNA Therapeutics
    10/22/2014

    Moderna Therapeutics, Karolinska Institutet (KI), and Karolinska University Hospital (KUH) have joined forces to discover and develop drugs using messenger RNA (mRNA) Therapeutics technology.

  2. AstraZeneca Bolsters Partnership With U Of Cambridge
    10/22/2014

    AstraZeneca and its global biologics R&D arm MedImmune announced four new collaborations with the University of Cambridge, all launched in an attempt to strengthen AZ’s existing partnership with the University as the company sets out to expand its research infrastructure in Cambridge.

  3. New Initiative Launched To Promote Biotech Education
    10/22/2014

    The Biogen Idec Foundation is offering up a $1.5 million grant in an effort to boost the biotechnology industry’s visibility.

  4. University Of Pennsylvania’s T-Cell Therapy Shows Promising Results
    10/22/2014

    The University of Pennsylvania has announced promising results of its novel chimeric antigen receptor (CAR) therapy for cancer.

  5. Lilly To Streamline Manufacturing Operations In 2015
    10/21/2014

    Eli Lilly announced its plans to close one of its three manufacturing plants in Puerto Rico by the end of next year.

  6. Janssen And Aduro Ink New Deal In Lung Cancer Immunotherapy
    10/21/2014

    Janssen Biotech and Aduro BioTech announced their second agreement to develop treatments for lung cancer using Aduro’s LADD immunotherapy platform.

  7. Batu Biologics Licenses Novel Oncology Peptide Drugs From UC San Diego
    10/21/2014

    Batu Biologics has acquired exclusive licensing rights to novel peptide drugs for oncology targets from the University of California San Diego (UCSD).

  8. ProMetic Seeks Orphan Status For Lead IPF Drug
    10/20/2014

    Biopharmaceutical company ProMetic Life Sciences announced its intent to pursue idiopathic pulmonary fibrosis (IPF) as an orphan indication for its lead drug candidate PBI-4050.

  9. New Multiple Myeloma Drug To Enter Clinical Trials
    10/20/2014

    Researchers at the Imperial College London have developed a new type of drug for treating multiple myeloma which will enter clinical trials in late 2015.

  10. Pall ForteBio Introduces Off-The-Shelf Dip And Read Anti-CHO HCP Detection Kit To Accelerate Drug Development
    10/20/2014

    Pall ForteBio LLC, a division of Pall Corp. and a leading supplier of instrumentation and analytics for accelerated drug discovery and development, has announced commercial availability of a new Dip and Read™ Anti-CHO (Chinese hamster ovary) Host Cell Protein (HCP) Detection Kit for quantitation of residual HCPs.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.